Ciphergen Diagnostics Announces Renewal of Cancer Research Collaboration With Johns Hopkins University School of Medicine
March 17 2005 - 9:00AM
PR Newswire (US)
Ciphergen Diagnostics Announces Renewal of Cancer Research
Collaboration With Johns Hopkins University School of Medicine
FREMONT, Calif., March 17 /PRNewswire-FirstCall/ -- Ciphergen
Diagnostics, a division of Ciphergen Biosystems, Inc.
(NASDAQ:CIPH), announced the renewal of its multi-year research
collaboration with the Johns Hopkins University School of Medicine
aimed at the discovery of novel protein biomarkers in the field of
cancer. The focus of the collaboration over the last five years has
been to discover and validate new diagnostic biomarkers that may
improve cancer detection, classify types of disease, and provide
disease monitoring. This collaboration led to the publication in
August 2004 in Cancer Research of a study which described the use
of Ciphergen's PatternTrack(TM) approach to discover three protein
biomarkers that form the basis of a potential clinical assay
designed to detect early stage ovarian cancer. The three biomarkers
when combined were able to diagnose early stage (I/II) ovarian
cancer with 74% sensitivity at 97% specificity. Over the past five
years the research has been led by Daniel W. Chan, Ph.D., Professor
of Pathology, Oncology, Urology, and Radiology and Director of the
Clinical Chemistry Division of the Department of Pathology and Eric
Fung M.D., Ph.D., Vice President of Clinical Affairs, Ciphergen's
Diagnostics Division. "We are excited to renew this research
collaboration with Johns Hopkins University School of Medicine. We
believe this collaboration will lead to the discovery of biomarkers
with clinical utility in cancer diagnosis and management, as well
as provide us with a better understanding of cancer biology and
pathophysiology," stated Dr. Fung. As part of the collaboration
Ciphergen will continue to provide financial support, technical
assistance, and access to advanced technology platforms through its
Biomarker Discovery Center(R) scientists. Johns Hopkins will
continue to contribute significant resources including cancer serum
samples and the clinical and scientific expertise of its physicians
and scientists. Ciphergen will continue to have access to the
commercial rights of the discoveries made through the collaboration
with Johns Hopkins. Gail Page, President of Ciphergen's Diagnostics
Division, stated, "We are privileged to continue our collaboration
with such dedicated and prestigious researchers. It is our belief
that this partnership will result in rigorously conducted research
that can be translated into commercial products that will benefit
patients and the health care system. This relationship exemplifies
a goal of translational medicine, which is to translate discoveries
into assays that provide the physician with decision support
tools." About Ciphergen Ciphergen's Diagnostics Division is
dedicated to the discovery of protein biomarkers and panels of
biomarkers and their development into protein molecular diagnostic
tests that improve patient care; and to providing collaborative
R&D services through its Biomarker Discovery Center(R)
laboratories for biomarker discovery for new diagnostic tests as
well as pharmacoproteomic services for improved drug toxicology,
efficacy and theranostic assays. Ciphergen's Biosystems Division
develops, manufactures and markets a family of ProteinChip(R)
Systems and services for clinical, research, and process proteomics
applications. ProteinChip Systems enable protein discovery,
characterization, identification and assay development to provide
researchers with predictive, multi-marker assay capabilities and a
better understanding of biological function at the protein level.
Additional information about Ciphergen can be found at
http://www.ciphergen.com/. Safe Harbor Statement Note Regarding
Forward-Looking Statements: For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such forward-looking
statements include statements regarding a potential clinical assay
designed to detect early stage ovarian cancer, the discovery of
biomarkers with clinical utility in cancer diagnosis and management
as well as providing a better understanding of cancer biology and
pathophysiology, translating research in the partnership into
commercial products that benefit patients and the healthcare
system, the ability to provide services that lead to improved
toxicology assays and diagnostic assays, and statements regarding
our Diagnostics Division. Actual results may differ materially from
those projected in such forward-looking statements due to various
factors, including Ciphergen's ability to validate an ovarian
cancer assay and/or develop other protein biomarkers as novel drug
targets, diagnostic or toxicology assays, and the Company's ability
to successfully commercialize such tests. Investors should consult
Ciphergen's filings with the Securities and Exchange Commission,
including its Form 10-Q dated November 9, 2004, for further
information regarding these and other risks of the Company's
business. NOTE: Ciphergen, ProteinChip and Biomarker Discovery
Center are registered trademarks of Ciphergen Biosystems, Inc.
DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers,
Investor Relations, of Ciphergen Biosystems, Inc., +1-510-505-2297
Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From May 2024 to Jun 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2023 to Jun 2024